Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
This study has been completed.
Sponsor:
Baxter Healthcare Corporation
Information provided by:
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT00161824
First received: September 8, 2005
Last updated: October 18, 2006
Last verified: October 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to another licensed TBE vaccine (Encepur® adults, with polygeline) (2 lots) in healthy volunteers aged 16 to 65 years.
| Condition | Intervention | Phase |
|---|---|---|
|
Encephalitis, Tick-Borne |
Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind |
| Official Title: | Single-Blind, Randomized, Multicenter Comparison of FSME IMMUN NEW and ENCEPUR: Safety and Tolerability of Two Vaccinations in Healthy Volunteers Aged 16 to 65 Years. |
Resource links provided by NLM:
Further study details as provided by Baxter Healthcare Corporation:
Eligibility| Ages Eligible for Study: | 16 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
Male and female volunteers were eligible for participation in this study if they:
- Were 16 years (from the 16th birthday) to 65 years (to the last day before the 65th birthday) old
- Were clinically healthy
- Had a negative pregnancy test at the first medical examination, if female and capable of bearing children
- Agreed to employ adequate birth control measures for the duration of the study, if female and capable of bearing children
- Provided written informed consent
- For volunteers under 18 years of age – written informed consent of the parents / guardian was available
- Agreed to keep a volunteer diary
Exclusion Criteria:
- History of any previous TBE vaccination
- History of TBE infection or show evidence of latent TBE infection (as demonstrated by screening ELISA > 126 VIEU/ml)
- History of allergic reactions, in particular to one of the components of the vaccine
- Previously received volume substitution with a product containing polygeline (stabilizer in ENCEPUR)
- Received antipyretics within 4 hours prior to the first TBE vaccination
- Suffer from a disease that cannot be effectively treated or stabilized
- Suffering from a disease (e.g. autoimmune disease) or were undergoing any form of treatment that could be expected to influence immunological functions
- Suffering from chronic, degenerative and/or inflammatory disease of the central nervous system
- Using any immunosuppressive drugs (e.g. local or systemic corticosteroids, chemotherapeutics)
- Had a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages)
- Had donated blood or plasma within one month of the study start
- Had received banked blood or immunoglobulins within one month of study entry
- Known to be HIV positive (a special HIV test was not required for the purpose of the study)
- Suffering from a febrile illness at study entry
- History of vaccination against yellow fever and / or Japanese B encephalitis
- Participating simultaneously in another clinical trial
- If female: pregnant or breast feeding
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00161824
Locations
| Poland | |
| Zespol Opieki Zdrowotnej w Debicy | |
| Debica, Poland, 33-200 | |
| Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A | |
| Kielce, Poland, 25-381 | |
| Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta" | |
| Krakow, Poland, 30-969 | |
| Szpital Jana Pawla II Oddzial Neuroinfekcji | |
| Krakow, Poland, 31-202 | |
| "Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego | |
| Krakow, Poland, 30-018 | |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Oddzial Pediatryczny | |
| Lubartow, Poland, 21-100 | |
| PANTAMED sp. z o.o. | |
| Olsztyn, Poland, 10-461 | |
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
| Principal Investigator: | Jerzy Romaszko, MD | PANTAMED sp. z o o. |
| Principal Investigator: | Jerzy Brzostek, MD | Zespol Opieki Zdrowotnej w Debicy |
| Principal Investigator: | Jerzy Dziduch, MD | Samodzielny Publiczny Zaklad Opieki Zdrowotnej Oddzial Pediatryczny |
| Principal Investigator: | Krystnyna Jurowska, MD | Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta" |
| Principal Investigator: | Marian Patrzalek, MD | Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A |
| Principal Investigator: | Krzysztof Sladek, MD | "Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego |
| Principal Investigator: | Ryszard Konior, MD | Szpital Jana Pawla II Oddzial Neuoinfekcji |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00161824 History of Changes |
| Other Study ID Numbers: | 208 |
| Study First Received: | September 8, 2005 |
| Last Updated: | October 18, 2006 |
| Health Authority: | Poland: Ministry of Health |
Additional relevant MeSH terms:
|
Encephalitis Encephalitis, Tick-Borne Central Nervous System Viral Diseases Virus Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections |
Encephalitis, Arbovirus Arbovirus Infections Tick-Borne Diseases Encephalitis, Viral RNA Virus Infections Flavivirus Infections Flaviviridae Infections |
ClinicalTrials.gov processed this record on May 16, 2013